Ception lands $63M in third round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Ception Therapeutics
|
$63M
|
Essex Woodlands Health Ventures |
Much of that money will be used to advance a late-stage biologic compound in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs. |
|
Proacta
|
$35M
|
Clarus Ventures |
Much of that money will be used to develop PR-104, a compound that is designed to kill cancer cells. |
|
Avesthagen
|
$32.5M
|
Fidelity International |
The money will go to R&D, infrastructure and the acquisition of technology companies. |
|
ActoGeniX
|
$25.9M
|
GIMV and Life Sciences Partners |
ActoGeniX is developing a pipeline of therapeutic products based on its TopActTM technology platform. |
|
Xcellerex
|
$11M
|
SCG Group and Kleiner Perkins Caufield and Byers |
Xcellerex is commercializing a new manufacturing program that uses disposable components to produce multiple products. |